Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 aflibercept ophthalmic study in Japan
jRCT2080224872Phase 3Completed
- Start
- Sep 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3 trial of aflibercept in well-being (2 arms). Started Sep 2019; status: completed.
02
Drugs
aflibercept
03
Conditions
well-being
Beyond the preview
Go deeper on jRCT2080224872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224872.